fluconazole has been researched along with Lymphoma, Non-Hodgkin in 6 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with amphotericin B(AMPH-B) and flucytosine(5-FC) was initiated as diagnosis of cryptococcus meningitis." | 1.37 | Disseminated cryptococcosis in a non-Hodgkin's lymphoma patient with late-onset neutropenia following rituximab-CHOP chemotherapy: a case report and literature review. ( Ainoda, Y; Fujita, T; Hirai, Y; Mori, N; Motoji, T; Shiseki, M; Shoji, T; Teramura, M; Totsuka, K; Yoshinaga, K, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirai, Y | 1 |
| Ainoda, Y | 1 |
| Shoji, T | 1 |
| Fujita, T | 1 |
| Yoshinaga, K | 1 |
| Shiseki, M | 1 |
| Mori, N | 1 |
| Teramura, M | 1 |
| Totsuka, K | 1 |
| Motoji, T | 1 |
| Nakagawa, Y | 1 |
| Kabbara, N | 1 |
| Lacroix, C | 1 |
| Peffault de Latour, R | 1 |
| Socié, G | 1 |
| Ghannoum, M | 1 |
| Ribaud, P | 1 |
| Chubachi, A | 1 |
| Miura, I | 1 |
| Ohshima, A | 1 |
| Nimura, T | 1 |
| Niitsu, H | 1 |
| Miura, AB | 1 |
| Horowitz, HW | 1 |
| Holmgren, D | 1 |
| Seiter, K | 1 |
| Marr, KA | 1 |
| White, TC | 1 |
| van Burik, JA | 1 |
| Bowden, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial to Evaluate the Safety and Tolerability of Nebulised Amphotericin B Lipid Complex (ABELCET®) in the Prophylaxis of Invasive Pulmonary Aspergillosis During Prolonged Neutropenia in Paediatric Patients With Acute Leukaemia[NCT01615809] | Phase 2 | 32 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The incidence of invasive pulmonary aspergillosis during the Abelcet® prophylactic treatment period was assessed by the relation between the number of patients with invasive pulmonary aspergillosis and the number of paediatric patients on prophylaxis with Acute Leukaemia (AL) undergoing intensive chemotherapy. (NCT01615809)
Timeframe: at the Baseline visit (week 1) and at the end of the profilaxis treatment phase, up to 6 weeks
| Intervention | participants (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 3 |
Percentage of deaths related to Invasive Pulmonary Aspergillosis during the prophylactic treatment period with Abelcet® in paediatric patients with Acute Leukaemia undergoing intensive chemotherapy. (NCT01615809)
Timeframe: at the Baseline visit (week 1) and at the end of the profilaxis treatment phase, up to 6 weeks
| Intervention | percentage of deaths (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 0 |
is assessed by the proportion of patients who discontinue prophylactic treatment with Abelcet® due to an adverse event that is related or not to the study drug or for intolerability to it. The last week of treatment will have a different calendar for each participant, depending on the number of cicles needed by each patient (it has been anticipated up to 5 cicles of 2-6 weeks each). (NCT01615809)
Timeframe: at the Baseline visit (week 1) and during the Last week of treatment, up to 6 weeks
| Intervention | participants (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 0 |
1 trial available for fluconazole and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciproflo | 1996 |
5 other studies available for fluconazole and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Disseminated cryptococcosis in a non-Hodgkin's lymphoma patient with late-onset neutropenia following rituximab-CHOP chemotherapy: a case report and literature review.
Topics: Aged; Amphotericin B; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Comb | 2011 |
[Prophylactic administration of fluconazole and itraconazole in febrile neutropenia associated with hematopoietic malignancy].
Topics: Fluconazole; Humans; Itraconazole; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic | 2006 |
Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy.
Topics: Adolescent; Adult; Anemia, Aplastic; Antifungal Agents; Candida; Candidiasis; Caspofungin; Echinocan | 2008 |
Notable clinical changes of hepatosplenic abscesses in febrile neutropenic patients receiving empiric antifungal treatment with azoles.
Topics: Abscess; Antifungal Agents; Candidiasis; Fever; Fluconazole; Humans; Leukemia; Liver Abscess; Lympho | 1994 |
Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation.
Topics: Adult; Antibiotic Prophylaxis; Antifungal Agents; Bone Marrow Transplantation; Candida albicans; Can | 1997 |